A B S T R A C T Since studies in animals and humans have shown that parathyroid hormone can stimulate bone formation and increase trabecular bone, and patients with primary and secondary hyperparathyroidism may exhibit osteosclerosis, we evaluated the effect of short-term administration of human parathyroid hormone, hPTH-(1-34), in patients with osteoporosis.
A B S T R A C T Since studies in animals and humans have shown that parathyroid hormone can stimulate bone formation and increase trabecular bone, and patients with primary and secondary hyperparathyroidism may exhibit osteosclerosis, we evaluated the effect of short-term administration of human parathyroid hormone, hPTH-(1-34), in patients with osteoporosis.
Six patients with osteoporosis underwent detailed studies including blood and urinary measurements of calcium, phosphate, and magnesium; 47Ca kinetic studies; and 18-d balance studies before and during the short-term administration (3-4 wk) of a daily subcutaneous injection of hPTH fragment given as 450 or 750 U/dose.
The mean fasting plasma calcium values rose slightly after hPTH-(1-34) administration, primarily in the high-dose group. There was no difference in the mean fasting plasma inorganic phosphate levels. The mean daily urinary excretion of calcium and phosphate was significantly increased in patients given the higher dose.
In patients given 450 U, net intestinal calcium absorption increased, phosphate absorption increased, calcium balance improved, and phosphate balance improved. In patients given 750 U, calcium balance and phosphate balance worsened.
47Ca kinetic studies showed a minimal increase in bone accretion rate, a decrease in the mean transit time of calcium in the exchangeable pools, and a decrease in the exchangeable-pool size. In all six patients there was an increased renal clearance of 47Ca as a result of hPTH-(1-34) administration.
These studies indicate that low doses of parathyroid INTRODUCTION Parathyroid hormone has multiple direct and indirect effects upon the skeleton, including increased synthesis and destruction of bone matrix, and increased uptake and release of bone mineral (1, 2) . It is well known that high doses of parathyroid hormone are catabolic to bone in animals, and excessive secretion of endogenous hormone reduces bone mass in humans and animals. The dose dependence of parathyroid hormone's effects upon bone metabolism in the human skeleton has not been adequately investigated, but multiple investigators have shown that low doses of parathyroid hormone are anabolic for trabecular bone in young rats (3) (4) (5) (6) (7) . Repeated injections of the hormone increase trabecular bone in such animals whether they are intact or previously thyroparathyroidectomized (6) . It has been impossible to evaluate the effects of low doses of parathyroid hormone on trabecular bone mass in humans in the past because the only available material was bovine parathyroid hormone, which provokes neutralizing antibodies in humans after several weeks of injections (8) . It is known, however, that osteosclerosis occasionally develops in patients with mild primary hyperparathyroidism (9, 10) and frequently occurs in patients with secondary hyperparathyroidism due to uremia (11) (12) (13) .
In recent years the sequence of human parathyroid hormone has been determined (14) (15) (16) . The biologically active amino-terminal portion of the human parathyroid hormone, hPTH-(1-34),' as well as various biologically active analogs and fragments of para-'Abbreviations used in this paper: hPTH, human parathyroid hormone.
thyroid hormone have been synthesized, and are being used to characterize details of the hormones actions on renal and skeletal tissues (17) (18) (19) . Definitive clinical studies have benefited from the availability of the synthetic peptide hPTH-(1-34), which is a pure compound, in contrast to the previously available bovine hormone preparation, which is a highly impure parathyroid extract with variable biological potency because of the presence of multiple hormone fragments of various strengths and biological activity. Synthetic hPTH-(1-34) produces all the known biological effects of the intact 84-amino acid hormone in vivo (19) , and increases bone mass when added in vitro to tissue cultures of embryonic mouse radiae (20) . A multicenter study had been organized to evaluate the effects of this peptide on bone mass in elderly humans with idiopathic osteoporosis. These studies show that the hPTH-(1-34) increases bone turnover in such patients and also increases trabecular bone in paired iliac-crest biopsies (21) (22) (23) (24) .
Optimum use of synthetic hPTH-(1-34) to stimulate bone turnover and increase bone mass in humans requires more detailed knowledge of the dose dependence of the effects of this peptide on bone in humans. The effects of different dosages of this synthetic peptide on bone mineral metabolism in humans have been reported only by Reeve et al. (25) , who studied the effects of three different doses of hPTH-(1-34) on calcium balance, renal tubular function, and skeletal turnover. Only two patients were studied, however, and the peptide dose was increased every 8 d. They concluded that the highest dose tended to cause bone breakdown. We report here more extended studies on six patients, each given either 450 or 750 U of hPTH-(1-34) daily for 18 d.
METHODS
Subjects. Six patients (five females and one male), 50-70 yr of age with osteoporosis were studied. The diagnosis was established by iliac-crest bone biopsy (26) , metacarpal measurements (27) , femoral trabecular index (Singh score) (28), gamma photon absorptiometry using the NorlandCameron bone mineral analyzer (29, 30) , and history of vertebral crush fractures (Table I) .
Bone biopsies in all patients except patients 2 and 5 were done after double-tetracycline labeling and analyzed by detailed histomorphometric analyses (26) , which are listed in Table II . Patient 2 did not present with vertebral crush fractures; however, the metacarpal cortical area and bone densitometry (distal radius) were >1 SD below the normal mean, the femoral trabecular index was reduced to 3.0, and a bone biopsy revealed osteoporosis. Plasma immunoreactive parathyroid hormone levels were determined using GP1 antiserum, and results are expressed as microliter equivalents of a standard hyperparathyroid human plasma (31) ; values were normal in all patients. Serum 25-hydroxylated vitamin D, measured by a competitive protein-binding technique (32) , was well within the normal range in all patients (44±16; mean-+-SD).
All patients had normal levels of serum alkaline phosphatase and had not sustained any fractures for at least 3 mo before they entered the study. All patients had a complete medical evaluation before entering the study. All had normal urinalysis, blood urea nitrogen, and serum creatinine. Creatinine clearance was normal in all patients when corrected for age (33) The experimental design used each patient as their own control. Since those patients on estrogens, androgens, or vitamin-D therapy had been on these medications for many months or years before being studied, it is unlikely that changes seen between the control and hormone administration periods were due to these concomitant medications.
A control study consisted ofan initial run-in period of 5-7 d to allow a steady state to be obtained. An 18-d 47Ca kinetic study was then performed, along with an 18-d study, divided into three 6-d periods of calcium, phosphate, and magnesium balance. At the end of this control period, a synthetic fragment of hPTH-(1-34) was given daily by subcutaneous injection. After hPTH-(1-34) was administered for 7-10 d, a second 18-d kinetic study was performed, during which hPTH-(1-34) was continued as a daily injection at 0600 h. All food and medication were withheld on the day that each 47Ca kinetic study began until 6 h after the 47Ca injection. Thereafter, the patient's total 24-h intake of food and medication was administered during the remaining 14-16 h. Treatment balance studies, begun on the day hPTH-(1-34) was started, consisted of four 6-d periods.
The balance technique followed was essentially that described by Reifenstein et al. (36) . All fecal specimens were initially frozen, and when ready for homogenation, were pooled into 6-d collection periods in a paint can, to which was added 95% alcohol, distilled water, and cellulose gum (Hercules Inc., Wilmington, Delaware). Lead balls (2-3 cm) 24 -h was pooled into bottles containing 10 ml of 6 N HCI from 0600 through 0600 h, and each collection was analyzed for calcium, phosphate, magnesium, creatinine, and hydroxyproline. Three times weekly during the study periods, fasting plasma was obtained for calcium, phosphate, magnesium, and creatinine determinations. In addition, on these same days, renal clearance of phosphate and creatinine was measured from 0600 through 0900 with the patient supine and fasting, to calculate the maximum tubular reabsorption capacity divided by the glomerular filtration rate (TmP/GFR) (38) .
Plasma and urine calcium and magnesium were analyzed by atomic absorption, and plasma and urine phosphate and creatinine by spectrophotometer (39, 40) . Urine hydroxyproline was analyzed by the method of Kivirikko et al. (41) .
47Ca kinetic studies were performed in each balance study with the patient in the fasting state (42) . 47CaCl2 dissolved in 5-10 ml of sterile acidified isotonic saline was given by rapid injection into an antecubital vein. Plasma samples were taken from the opposite antecubital vein through an indwelling catheter at 2, 4, 6, 8, 11, 15, 20, 25, 30, 35, 45, 60 ,80, 100, 120, 180, 240, 300, 360, 480, 600, and 720 min, and at 1, 1.5, 2, 3, and 4 d after the isotopic injection. These samples were then analyzed for radioactivity and stable calcium. The radioactivity in the plasma was measured with a 3-in sodium iodide well crystal. The radioactivity was expressed as the fraction of the injected dose per gram of calcium. Urine was placed into 24-h pooled collections as described above and counted in 2,000-ml Marinelli-type vessels using a 3-in sodium iodide solid crystal. Urine specific activity was expressed as the fraction of the injected dose per gram of calcium. The cumulative fraction of the injected dose was also calculated. Fecal specimens were collected for 18 d after the isotope injection and pooled into three 6-d pools which were individually counted in a fashion similar to that used for urine. The radioactivity recovered was expressed as the cumulative fraction ofthe injected dose. 47Ca counting was done above 0.4 million electron volts (MEV) to eliminate radiation from 47Sc, the radioactive decay product of 47Ca. We counted 51Cr and 47Ca radioactivity in the feces simultaneously, using separate 47Ca and 5"Cr standards and a 1028-channel gamma spectrometer, Norland/Ino-Tech, Fort Atkinson, Wis. The 5"Cr was counted with a window of 0.276-0.356 MEV and 47Ca using a window of 0.460-1.440 MEV, and all count rates were corrected for isotope crossover. All samples were counted for a length of time to allow a 2-3% coefficient of variation for the net count rate (43) . Endogenous fecal calcium is estimated from the amount of radioactivity appearing in the feces after the intravenous injection of47Ca. Data analysis. Blood and urine samples were compared in the control and treatment period in individual patients by using an unpaired t test with allowance for possible unequal variances. When comparing the effects of hPTH-(1-34) on calcium, phosphate, and magnesium balance, and on intestinal absorption, statistical significance was assessed by a nested analysis of variance with two levels for treatment (control vs. peptide) and dose (high vs. low) and seven measures for each subject. The effects of treatment were tested separately at each dose, and the dependence of the treatment effect on the peptide dose was also tested, the variance within cells being used as the error term (45) . In analyzing the net intestinal absorption and balance studies, the 6-d periods were used for each patient rather than the mean of the studies, so that the analysis of variance would take into account experimental variations in balance and absorption. 47Ca kinetic studies were analyzed according to a noncompartmental model (46) . The turnover time of calcium in the exchangeable pools of bone was determined by the method described by Reeve (47) .
RESULTS
No patient experienced symptoms from the hormone administration, nor were any toxic renal, hepatic, hematologic, or other effects detected.
Calcium metabolism
Blood. The mean levels of fasting plasma calcium were slightly but significantly higher (P < 0.01) after hPTH-( 1-34) administration (9.42 ±0.04 mg/dl) than those observed in the control period (9.29±0.04 mg/dl) (Table III) . This rise appeared to be primarily attributable to those patients receiving the higher dose of hPTH-(1-34). All levels of plasma calcium remained in the normal range except patient 5, in whom they rose to a maximum of 10.7 mg/dl 6 h after injection of hPTH-(1-34) but returned to normal within 12 h after hPTH-(1-34) injection.
Urine. An increase in urinary calcium excretion was evident 3-4 d after beginning hPTH-(1-34) therapy (Table III and Fig. 1 Fig. 2 ). Each patient in this group had an increase in calcium absorption efficiency, net intestinal absorption, and true intestinal absorption (corrected for endogenous fecal calcium) as a result of hPTH-(1-34) administration. In contrast, patients receiving the high dose tended to show a worsening in intestinal calcium absorption as a result of hPTH-(1-34), but this was not statistically significant.
Balance. There were significant changes in calcium balance in both the patients receiving the low dose and those receiving the high dose (Table III and Fig. 2) . The changes were in opposite directions, however, patients receiving the low dose showed a mean improvement in calcium balance of 110%. Comparison using the individual periods during the control study and when 450 U hPTH-(1-34) was administered, each patient acting as his/her own control, showed that the mean increase of 85 mg/d was statistically significant (P < 0.05) by analysis of variance.
On the other hand, the high dose of hPTH-(1-34) resulted in a negative calcium balance. The decrease in calcium balance averaged 149 mg/d.
In no patient did endogenous fecal calcium change more than 20 mg/d as a result of hPTH-(1-34) administration, and urine calcium stayed the same or increased slightly during hPTH-(1-34) administration. Thus, the improvement in calcium balance seen on the lower dose is explained by an increase in net intestinal absorption (Fig. 2) . 47Ca turnover. As determined by 47 calcium kinetic studies, there was no substantial change in skeletal accretion (Table IV) . The biggest change was seen in patient 5 hPTH-(1-34) and increased by a mean of 52% in the three patients receiving the higher dose. Because of the small number of determinations, no statistical tests were feasible. As shown in Fig. 3 , there was a greater cumulative excretion of the injected 47Ca in all patients as a result of hPTH-(1-34) treatment, amounting to an increase of 5.2% in the patients receiving the low dose and a similar increase (7.2%) in those receiving the high dose. These changes were entirely due to increased renal 47Ca excretion, which occurred despite a lower plasma 47Ca/total concentration in five of the six patients (Fig. 3) .
Serum alkaline phosphatase and plasma creatinine levels did not change with hPTH-(1-34) administration and remained normal.
Hydroxyproline excretion increased significantly (P < 0.01) only in patient 5, who was receiving the higher dose.
Phosphate metabolism
Blood. Although in the group as a whole, there was no statistically significant difference in the mean level of fasting plasma inorganic phosphate as a result of hPTH-(1-34) administration (3.57 +0.07 control vs. 3 .60+0.10 treatment), statistically significant increments were observed in patients 4 and 5; patient 6 had a significant decrease (Table V) . All three of these patients were receiving the higher dose of hPTH- . In no patient was hypophosphatemiaproduced.
Urine. The mean daily urinary excretion of phosphate was significantly increased in the patients receiving the higher dose of hPTH-(1-34) (P < 0.01; mean increase 87 mg/d) ( Table V and Fig. 1 
treatment).
In all patients there was a significant (P < 0.01) increase in the amount of phosphate excreted during the 3 h (0600-0900) after hormone administration as compared with the total 24-h urinary phosphate excretion. The low-dose group showed a mean increase Fig. 2 ). In the high-dose group the mean decreased 35%, owing primarily to patient 4. By analysis of variance using the individual collection FIGURE 3 Blood and urine 47Ca kinetic data for patients given low (A) and high doses (B) of hPTH-(1-34) during control and treatment studies. 0, The control study; *, the treatment study. All data points are the mean of the patients in each group. Note that the upper panels represent blood and urine 47Ca specific activity, whereas the lower panels represent cumulative fraction of the injected 47Ca excreted in the urine.
Short-term Effects of Human Parathyroid Hormone-(1 -34) in Osteoporosis Fig. 2 ). This was statistically significant (P < 0.01) when all individual periods were used in the analysis of variance. This improvement was primarily due to an increase in intestinal phosphate absorption.
Again these effects of the two different peptide doses on balance were significantly different (P < 0.01).
Phosphate balance became negative in those patients receiving the high dose of hPTH-(1-34) (P < 0.01). The mean decrease in balance of 245% over control represented a mean of 178 mg phosphate/d. This resulted both from a decrease in intestinal phosphate absorption of 91 mg/d, and an increase in urinary phosphate excretion of 87 mg/d.
Magnesium metabolism
The mean levels of fasting plasma magnesium were significantly lowered (P < 0.01) by hPTH-(1-34) (1.91+0.02 control vs. 1.75+0.02 mg/dl treatment) with both doses and was significantly lowered (P < 0.01) in all patients except patient 2, who showed no change.
There were no consistent differences in the mean urinary excretion of magnesium, net intestinal magnesium absorption, and magnesium balance. The lowered plasma magnesium levels were perhaps due to renal losses too small to be appreciated.
DISCUSSION
Several results of the present study are pertinent with regard to the long-term use of this agent to alter bone metabolism in patients with osteoporosis.
In the present study, patients receiving the higher dose ( In contrast to these effects, patients receiving the lower dose (450 U) ofhPTH-(l -34) showed no increase in urinary phosphate excretion and only a small increase in urinary calcium excretion, and their calcium and phosphate balances either improved or remained essentially unchanged. Such improvements were largely related to improved intestinal calcium and phosphate absorption. These improvements occurred without the production of hypercalcemia or hypophosphatemia and probably indicate net bone uptake of both ions. The peptide apparently has a narrow range of dose dependence. A biphasic dose-response relation has also been seen in various animal studies (49) , and suggests induction of some counter-regulatory effect or effects, the nature of which is unknown.
A surprising finding in this study was the lack of a more marked effect of hPTH-(1-34) on intestinal calcium and phosphate absorption in view of the known stimulatory effect of parathyroid hormone on the renal 25-hydroxyvitamin-D-1-hydroxylase system (50) (51) (52) and the high intestinal calcium absorption reported in many patients with primary hyperparathyroidism (53). Birge et al. (54) showed in one patient that there were delayed effects of parathyroid hormone on intestinal calcium absorption. Recent evidence has indicated the need for prolonged (many hours) elevation of parathyroid hormone in blood before serum levels of 1,25-dihydroxyvitamin D3 increase (55) . Blood levels of hPTH-(1-34) in our patients after a single subcutaneous dose, estimated by radioimmunoassay, suggest rapid absorption and high but transient blood levels of the peptide. This may explain why the peptide failed to increase intestinal calcium absorption consistently. More frequent administration of parathyroid hormone may be needed to increase intestinal calcium and phosphate absorption. Patients with primary hyperparathyroidism have increased phosphate absorption (56, 57) , whereas the acute administration of parathyroid hormone to normal subjects does not alter radiophosphorus absorption (58) .
A second important aspect of this study concerns the time-related effects of this hormone on bone. There are almost no other available data concerning the early effects of synthetic hPTH-(1-34) or any other parathyroid hormone fragment on bone turnover in humans. Some studies have evaluated bone mineral metabolism in patients treated chronically with hPTH-(1-34) for 6 mo (21) (22) (23) (24) . In all patients in the present study, hPTH-(1-34) accelerated turnover of the labile calcium pool, as shown by a decrease in the mean transit time of the exchangeable pool and a decrease in the size of this pool. This finding shows that as little as several weeks of daily hPTH-(1-34) therapy accelerates bone calcium turnover. This acceleration was associated with a more rapid decrease in blood and urine 47Ca specific activity plus an increase in renal excretion of 47Ca as a result of hPTH-(1-34) in both groups. The47Ca kinetic study did not show any significant changes in bone accretion after short-term hPTH-(1-34) administration, a finding substantiated by the lack of any change in alkaline phosphatase activity. These changes are in marked contrast to those seen in another study after more prolonged hPTH-(1-34) administration (47) . In that study, hPTH-(1-34) administration for 6 mo accelerated the skeletal 47Ca turnover time threefold or more and markedly stimulated skeletal 47Ca accretion.
A related example of the time-dependent response to hPTH-(1-34) administration is provided by tjhe urinary calcium measurements (Fig. 1) . During the first 2 wk of hormone administration, there is a definite increase in renal calcium excretion, which then appears to reach a plateau for the remainder of the study. An interesting finding was the marked increase in urinary phosphate excretion during the 3 h after hPTH-(1-34) administration as compared to the 24-h collection. It appears that there was a burst of phosphate excretion during this time and then a reduced phosphate excretion during the remainder of the day in all patients except 4 and 5, so that the 24-h excretion was not markedly different from control. Phosphate excretion was not reduced in patients 4 and 5 for the remainder of the day. Total phosphate excretion increased significantly in these subjects owing at least in part to net bone breakdown.
Although reports indicate an increase in bone turnover and in trabecular bone volume in subjects treated chronically with hPTH-(1-34) (21-24),the failure ofintestinal calcium absorption and calcium balance to increase consistently would seem to limit the long-term anabolic effects of this agent in patients with osteoporosis. Further study of the mechanism of the effect of parathyroid hormone on the skeleton as well as the Short-term Effects of Human Parathyroid Hormone-(I -34) in Osteoporosiseffect of other concomitantly administered agents to increase intestinal absorption or reduce bone resorption would seem to be indicated if the therapeutic potential of this hormone in osteoporosis is to be meaningfully tested.
